# Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

> **NCT01721837** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 4340 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01721837
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 4340 (ACTUAL)
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721837, "Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01721837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*